A E Kaufman1, K Patel2, K Goyal3, D O'Leary4, N Rubin5, D Pearson3, K Bohjanen3, A Goyal3. 1. Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, MI, USA. 2. Department of Radiation Oncology, University of Minnesota, Minneapolis, MN, USA. 3. Department of Dermatology, University of Minnesota, Minneapolis, MN, USA. 4. Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN, USA. 5. Biostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Abstract
BACKGROUND: Prior studies have demonstrated improved disease-specific survival of mycosis fungoides (MF) patients over the last 50 years. OBJECTIVE: To analyse patterns of survival and incidence from 1973 to 2016 and determine whether apparent improvements in MF-specific survival are due to lead-time bias rather than improvements in treatment. METHODS: We performed an analysis of 10 155 patients diagnosed with MF from 1973 to 2016 in the United States cancer registries of SEER-18. We also performed a literature review of papers including stage data for unselected populations of MF patients prior to 2000. RESULTS: Incidence of MF increased from 3.0 per million person-years in the 1970s to 5.9 in the 2010s. For all cohorts, non-Hodgkin lymphoma (including MF) was the leading cause of death. Survival analysis demonstrated marked improvement in disease-specific and overall survival from the 1970s to 2010s. Based on systematic review of the literature, 32%-73% of patients diagnosed prior to 2000 were diagnosed with early-stage disease, as opposed to 81% of patients in the SEER 2000-2016 cohort (P < 0.035 for all cohorts). CONCLUSIONS: Although there have been improvements in MF-related survival over the last 50 years, these may reflect improvements in our ability to diagnose early-stage disease rather than improved treatment.
BACKGROUND: Prior studies have demonstrated improved disease-specific survival of mycosis fungoides (MF) patients over the last 50 years. OBJECTIVE: To analyse patterns of survival and incidence from 1973 to 2016 and determine whether apparent improvements in MF-specific survival are due to lead-time bias rather than improvements in treatment. METHODS: We performed an analysis of 10 155 patients diagnosed with MF from 1973 to 2016 in the United States cancer registries of SEER-18. We also performed a literature review of papers including stage data for unselected populations of MFpatients prior to 2000. RESULTS: Incidence of MF increased from 3.0 per million person-years in the 1970s to 5.9 in the 2010s. For all cohorts, non-Hodgkin lymphoma (including MF) was the leading cause of death. Survival analysis demonstrated marked improvement in disease-specific and overall survival from the 1970s to 2010s. Based on systematic review of the literature, 32%-73% of patients diagnosed prior to 2000 were diagnosed with early-stage disease, as opposed to 81% of patients in the SEER 2000-2016 cohort (P < 0.035 for all cohorts). CONCLUSIONS: Although there have been improvements in MF-related survival over the last 50 years, these may reflect improvements in our ability to diagnose early-stage disease rather than improved treatment.
Authors: Francine Foss; Steven M Horwitz; Bertrand Coiffier; Nancy Bartlett; Leslie Popplewell; Barbara Pro; Lauren C Pinter-Brown; Andrei Shustov; Richard R Furman; Corinne Haioun; Tony Koutsoukos; Owen A O'Connor Journal: Clin Lymphoma Myeloma Leuk Date: 2012-04-26
Authors: Youn H Kim; Rein Willemze; Nicola Pimpinelli; Sean Whittaker; Elise A Olsen; Annamari Ranki; Reinhard Dummer; Richard T Hoppe Journal: Blood Date: 2007-03-05 Impact factor: 22.113
Authors: E A Sausville; J L Eddy; R W Makuch; A B Fischmann; G P Schechter; M Matthews; E Glatstein; D C Ihde; F Kaye; S R Veach Journal: Ann Intern Med Date: 1988-09-01 Impact factor: 25.391
Authors: Joseph A Miccio; Lynn D Wilson; Benjamin H Kann; Vikram Jairam; Jason Beckta; Francine M Foss; Debra N Yeboa Journal: Anticancer Res Date: 2019-01 Impact factor: 2.480
Authors: Pamela B Allen; Subir Goyal; Tim Niyogusaba; Colin O'Leary; Amy Ayers; Erica S Tarabadkar; Mohammad K Khan; Mary Jo Lechowicz Journal: JAMA Dermatol Date: 2022-09-07 Impact factor: 11.816
Authors: Caitlin M Brumfiel; Meera H Patel; Pranav Puri; Jake Besch-Stokes; Scott Lester; William G Rule; Nandita Khera; Jason C Sluzevich; David J DiCaudo; Nneka Comfere; N Nora Bennani; Allison C Rosenthal; Mark R Pittelkow; Aaron R Mangold Journal: Curr Treat Options Oncol Date: 2021-09-27